Current knowledge and future challenges in takotsubo syndrome: Part 2-treatment and prognosis

Francesco Santoro*, Adriana Mallardi, Alessandra Leopizzi, Enrica Vitale, Elias Rawish, Thomas Stiermaier, Ingo Eitel, Natale D. Brunetti

*Korrespondierende/r Autor/-in für diese Arbeit
20 Zitate (Scopus)

Abstract

Takotsubo syndrome (TTS) represents a form of acute heart failure featured by reversible left ventricular systolic dysfunction. The management during the acute phase is mainly performed with supportive pharmacological (diuretics, ACE-inhibitors/angiotensin-receptor blockers (ARBs), anticoagulants, antiarrhythmics, non-catecholamine inotropics (levosimendan), and non-pharmacological (mechanical circulatory and respiratory support) therapy, due to the wide clinical presentation and course of the disease. However, there is a gap in evidence and there are no randomized and adequately powered studies on clinical effectiveness of therapeutic approaches. Some evidence supports the use ACE-inhibitors/ARBs at long-term. A tailored approach based on cardiovascular and noncardiovascular risk factors is strongly suggested for long-term management. The urgent need for evidence-based treatment approaches is also reflected by the prognosis following TTS. The acute phase of the disease can be accompanied by various cardiovascular complications. In addition, long term outcome of TTS patients is also related to non-cardiovascular comorbidities. Physical triggers such as hypoxia and acute neurological disorders in TTS are associated with a poor outcome.

OriginalspracheEnglisch
Aufsatznummer468
ZeitschriftJournal of Clinical Medicine
Jahrgang10
Ausgabenummer3
Seiten (von - bis)1-9
Seitenumfang9
ISSN2077-0383
DOIs
PublikationsstatusVeröffentlicht - 01.02.2021

Strategische Forschungsbereiche und Zentren

  • Zentren: Universitäres Herzzentrum Lübeck (UHZL)

DFG-Fachsystematik

  • 2.22-12 Kardiologie, Angiologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Current knowledge and future challenges in takotsubo syndrome: Part 2-treatment and prognosis“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren